metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Update on fungemia in oncology and hematology
Journal Information
Vol. 29. Issue S4.
Update on infectious diseases
Pages 42-47 (March 2011)
Share
Share
Download PDF
More article options
Vol. 29. Issue S4.
Update on infectious diseases
Pages 42-47 (March 2011)
Full text access
Update on fungemia in oncology and hematology
Actualización en fungemia en oncohematología
Visits
3017
Enric Carrerasa,
Corresponding author
carreras@clinic.ub.es

Correspondence author.
, Lourdes Vázquezb, José Luis Rodríguez Tudelac, Albert Pahisad, José Ramón Azanzae, Montserrat Roviraa, Rafael de la Cámaraf
a Servicio de Hematología, Hospital Clínic, Barcelona, Spain
b Servicio de Hematología, Hospital Universitario, Salamanca, Spain
c Centro Nacional de Microbiología, Majadahonda, Madrid, Spain
d Servicio de Enfermedades Infecciosas, Hospital de la Vall d’Hebron, Barcelona, Spain
e Clínica Universitaria de Navarra, Pamplona, Spain
f Servicio de Hematología, Hospital de la Princesa, Madrid, Spain
This item has received
Article information
Abstract

The present article is an update of the literature on fungemia in onco-hematologic patients. A multidisciplinary group of Spanish physicians with an interest in this field selected the most important papers published lately. Papers from the fields of epidemiology, risk factors, pathogenesis, diagnosis, outcome, prevention and treatment are discussed. Important aspects of these studies include the assessment of different strategies in the management of fever in neutropenic patients. Moreover, early identification of patients at risk of fungal infections, as well as identification of patients at risk for fluconazole-resistant strains are topics of increasing interest.

Keywords:
Fungemia
Oncology
Hematology
Resumen

El trabajo que se presenta es una revisión de la bibliografía reciente más relevante del último año publicada en relación con la funginemia en pacientes oncohematológicos. Un grupo multidisciplinar compuesto por diferentes especialistas españoles con interés en este campo revisan los artículos más novedosos. Los trabajos pertenecen a áreas de epidemiología, factores de riesgo, patogénesis, diagnóstico, evolución, prevención y tratamiento. Se analizan diferentes aspectos, incluyendo estrategias del manejo de la fiebre en el paciente neutropénico. La identificación precoz de factores de riesgo de infección fúngica, así como de los factores de riesgo de infección por cepas resistentes a fluconazol es objetivo de especial interés.

Palabras clave:
Fungemia
Oncología
Hematología
Full text is only aviable in PDF
References
[1.]
I.R. Camps.
Risk factors for invasive fungal infections in haematopoietic stem cell transplantation.
International J Antimicrob Agents, 32 (2008), pp. S119-S123
[2.]
N.G. Almyroudis, B.H. Segal.
Prevention and treatment of invasive fungal diseases in neutropenic patients.
Curr Opin Infect Dis, 22 (2009), pp. 385-393
[3.]
B. De Pauw, T.J. Walsh, J.P. Donnelly, D.A. Stevens, J.E. Edwards, T. Calandra, et al.
Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.
Clin Infect Dis, 46 (2008), pp. 1813-1821
[4.]
L. Pagano, M. Caira, A. Nosari, M.T. Van Lint, A. Candoni, M. Offidani, et al.
Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study–Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne.
Clin Infect Dis, 45 (2007), pp. 1161-1170
[5.]
R. Hachem, H. Hanna, D. Kontoyiannis, Y. Jiang, I. Raad.
The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Cancer, 112 (2008), pp. 2493-2499
[6.]
D.P. Kontoyiannis, K.A. Marr, B.J. Park, B.D. Alexander, E.J. Anaissie, T.J. Walsh, et al.
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database.
Clin Infect Dis, 50 (2010), pp. 1091-1100
[7.]
M. Nucci, E. Anaissie.
Fusarium infections in immunocompromised patients.
Clin Microbiol Rev, 20 (2007), pp. 695-704
[8.]
K. Suzuki, K. Nakase, T. Kyo, T. Kohara, Y. Sugawara, T. Shibazaki, et al.
Fatal Trichosporon fungemia in patients with hematologic malignancies.
Eur J Haematol, 84 (2010), pp. 441-447
[9.]
J. Jensen, P. Muñoz, J. Guinea, M. Rodríguez-Creixems, T. Peláez, E. Bouza.
Mixed fungemia: incidence, risk factors, and mortality in a general hospital.
Clin Infect Dis, 44 (2007), pp. e109-e114
[10.]
M.A. Slavin, T.C. Sorrell, D. Marriott, K.A. Thursky, Q. Nguyen, D.H. Ellis, et al.
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
J Antimicrob Chemother, 65 (2010), pp. 1042-1051
[11.]
W.W. Hope, G.L. Drusano, C.B. Moore, A. Sharp, A. Louie, T.J. Walsh, et al.
Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis.
Antimicrob Agents Chemother, 51 (2007), pp. 285-295
[12.]
M.G. Netea, F. Van de Veerdonk, I. Verschueren, J.W. Van der Meer, B.J. Kullberg.
Role of TLR1 and TLR6 in the host defense against disseminated candidiasis.
FEMS Immunol Med Microbiol, 52 (2008), pp. 118-123
[13.]
A. Safdar.
Antifungal immunity and adjuvant cytokine immune enhancement in cancer patients with invasive fungal infections.
Clin Microbiol Infect, 13 (2007), pp. 1-4
[14.]
J. Guinea, S. Recio, P. Escribano, M. Torres-Narbona, T. Peláez, C. Sánchez-Carrillo, et al.
Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia.
J Clin Microbiol, 48 (2010), pp. 2205-2212
[15.]
P.G. Pappas, C.A. Kauffman, D. Andes, D.K. Benjamin Jr, T.F. Calandra, J.E. Edwards Jr, et al.
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis, 48 (2009), pp. 503-535
[16.]
A.C. Reboli, C. Rotstein, P.G. Pappas, S.W. Chapman, D.H. Kett, D. Kumar, et al.
Anidulafungin versus fluconazole for invasive candidiasis.
N Engl J Med, 356 (2007), pp. 2472-2482
[17.]
D.L. Horn, L. Ostrosky-Zeichner, M.I. Morris, A.J. Ullmann, C. Wu, D.N. Buell, et al.
Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials.
Eur J Clin Microbiol Infect Dis, 29 (2010), pp. 223-229
Copyright © 2011. Elsevier España S.L.. All rights reserved
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos